DUBLIN--(BUSINESS WIRE)--The \"Global Cancer Biomarkers Market Analysis 2019\" report has been added to ResearchAndMarkets.com's offering.<\/p>\n
The Global Cancer Biomarkers market is expected to reach $37.99 billion by 2026 growing at a CAGR of 14.2% from 2018 to 2026.<\/p>\n
Factors such as rise in technological advancements and increase in Incidence of Cancer diseases are driving the market growth. Though, high capital investment and technical issues related to sample collection and storage are projected to inhibit the growth of the market. Moreover, emerging economies and personalized medicine may provide ample opportunities for the market growth.<\/p>\n
By biomarker type, protein biomarkers segment acquired significant growth in the market is mainly attributed to the tremendous capability of protein biomarkers in cancer detection, diagnostics, prognostics, and clinical & therapeutic applications; and minimal cost of the protein biomarker tests as contrasted with genetic biomarker tests. The rising focus of pharmaceutical organizations towards the discovery of protein biomarkers is additionally expected to fuel the development of this market during the forecast period.<\/p>\n
The key vendors mentioned are Qiagen N.V., Thermo Fisher Scientific, GE Healthcare, Roche Diagnostics, Abbott Laboratories, Illumina, Danaher Corporation, Agilent Technologies, Sysmex Corporation, Merck & Co., Quest Diagnostics, Becton, Dickinson and Company, Hologic, Myriad Genetics, Bio-Rad Laboratories and Biomrieux S.A.<\/p>\n
Key Questions Answered in this Report<\/p>\n
Key Topics Covered <\/p>\n
1 Market Synopsis <\/p>\n
2 Research Outline <\/p>\n
2.1 Research Snapshot<\/p>\n
2.2 Research Methodology<\/p>\n
2.3 Research Sources<\/p>\n
2.3.1 Primary Research Sources<\/p>\n
2.3.2 Secondary Research Sources<\/p>\n
3 Market Dynamics <\/p>\n
3.1 Drivers<\/p>\n
3.2 Restraints<\/p>\n
4 Market Environment <\/p>\n
4.1 Bargaining power of suppliers<\/p>\n
4.2 Bargaining power of buyers<\/p>\n
4.3 Threat of substitutes<\/p>\n
4.4 Threat of new entrants<\/p>\n
4.5 Competitive rivalry<\/p>\n
5 Global Cancer Biomarkers Market, By Category <\/p>\n
5.1 Introduction<\/p>\n
5.2 Cancer Biomakers of Disease<\/p>\n
5.3 Cancer Biomakers of Exposure<\/p>\n
6 Global Cancer Biomarkers Market, By Method <\/p>\n
6.1 Introduction<\/p>\n
6.2 Assay Development<\/p>\n
6.3 Biomarkers and Testing<\/p>\n
6.4 Sample Preparation<\/p>\n
7 Global Cancer Biomarkers Market, By Biomarker Type <\/p>\n
7.1 Introduction<\/p>\n
7.2 Cancer Antigen 15-3 (CA 15-3)<\/p>\n
7.3 Cancer Antigen 27-29 (CA27-29)<\/p>\n
7.4 Carbohydrate Antigen 19-9 (CA 19-9)<\/p>\n
7.5 Carcinoembryonic antigen (CEA)<\/p>\n
7.6 Epigenetic Biomarkers<\/p>\n
7.7 Genetic Biomarkers<\/p>\n
7.8 Glass Transition Temperature (Tg)<\/p>\n
7.9 Glyco-biomarkers<\/p>\n
7.10 Glycomic Biomakers<\/p>\n
7.11 Glycoprotein Biomarkers<\/p>\n
7.12 Human Chorionic Gonadotropin (Hcg)<\/p>\n
7.13 Human Epidermal Growth Factor Receptor 2 (HER2)<\/p>\n
7.14 Human Epididymis Protein 4 (HE4)<\/p>\n
7.15 Metabolic Biomakers<\/p>\n
7.16 Microsatellite Instability (MSI) \/ Measles, Mumps and Rubella (MMR)<\/p>\n
7.17 Protein Biomarkers<\/p>\n
7.18 Proteomic Biomarkers<\/p>\n
7.19 Risk of Ovarian Malignancy Algorithm (ROMA)<\/p>\n
7.20 Tumor Mutational Burden (TMB)<\/p>\n
7.21 Tumor-Infiltrating Lymphocytes (TILs)<\/p>\n
8 Global Cancer Biomarkers Market, By Cancer Type <\/p>\n
8.1 Introduction<\/p>\n
8.2 Bladder Cancer<\/p>\n
8.3 Blood Cancer<\/p>\n
8.4 Breast Cancer<\/p>\n
8.5 Cervical Cancer<\/p>\n
8.6 Colorectal Cancer (CRC)<\/p>\n
8.7 Kidney Cancer<\/p>\n
8.8 Leukemia<\/p>\n
8.9 Liver Cancer<\/p>\n
8.10 Lung Cancer<\/p>\n
8.11 Melanoma<\/p>\n
8.12 Non-Hodgkin's Lymphoma<\/p>\n
8.13 Ovarian Cancer<\/p>\n
8.14 Prostate Cancer<\/p>\n
8.15 Stomach Cancer<\/p>\n
8.16 Thyroid Cancer<\/p>\n
9 Global Cancer Biomarkers Market, By Technology <\/p>\n
9.1 Introduction<\/p>\n
9.2 Bioinformatics<\/p>\n
9.3 Cytogenetics-based Tests<\/p>\n
9.4 Imaging Technologies<\/p>\n
9.5 Immunoassays<\/p>\n
9.6 IVD Multivariate Index Assays<\/p>\n
9.7 Omic technologies<\/p>\n
10 Global Cancer Biomarkers Market, By Test Type <\/p>\n
10.1 Introduction<\/p>\n
10.2 Alpha-Fetoprotein (AFP) Tests<\/p>\n
10.3 Anaplastic Lymphoma Receptor Tyrosine Kinase Gene (ALK) Tests<\/p>\n
10.4 BReast CAncer gene (BRCA) Tests<\/p>\n
10.5 Cancer Antigen (CA) Tests<\/p>\n
10.6 Carcinoembryonic Antigen (CEA) Tests<\/p>\n
10.7 Circulating Tumor Cell (CTC) Tests<\/p>\n
10.8 Companion Diagnostic Tests (CDx)<\/p>\n
10.9 Estimated Glomerular Filtration Rate (EGFR) Mutation Tests<\/p>\n
10.10 Human Epidermal Growth Factor Receptor 2 (HER2) Tests<\/p>\n
10.11 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation Tests<\/p>\n
10.12 Laboratory Developed Tests (LDTs)<\/p>\n
10.13 Prostate-specific Antigen (PSA) Tests<\/p>\n
11 Global Cancer Biomarkers Market, By Analytical Technique <\/p>\n
11.1 Introduction<\/p>\n
11.2 Immunohistochemistry (IHC)<\/p>\n
11.3 Next Generation Sequencing (NGS)<\/p>\n
11.4 Polymerase Chain Reaction (PCR)<\/p>\n
12 Global Cancer Biomarkers Market, By Product <\/p>\n
12.1 Introduction<\/p>\n
<\/p>\n
Excerpt from: DUBLIN--(BUSINESS WIRE)--The \"Global Cancer Biomarkers Market Analysis 2019\" report has been added to ResearchAndMarkets.com's offering. The Global Cancer Biomarkers market is expected to reach $37.99 billion by 2026 growing at a CAGR of 14.2% from 2018 to 2026 Continue reading
\nGlobal Cancer Biomarkers Market, Forecast to 2026 - Emerging Economies & Personalized Medicine to Provide Ample Industry Opportunities -...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"